The company grew nearly 26% for 3Q20, driven by continuing favorable coverage policies in the U.S. and backlogged procedures in July.

The company grew +1.5% in 3Q20. While spine surgery volume is approaching pre-COVID levels, the company does not expect overall market growth in 2020.

The progressive return of elective procedures and demand for Mako drove the company's V-shaped recovery from the second quarter pandemic low point.

While the company improved sequentially, weakness in emerging markets, and significant knee replacement losses hobbled its recovery.

The company grew its soon to be divested orthopedic franchise +5.1% in 3Q20 as momentum from backlogged procedures carried into the third quarter.

The company's revenue declined -7.4% in 3Q20 as capital sales remain slow, and the lack of team sports activity depresses sports medicine procedure volumes.

The company grew +10% in 3Q20, driven by U.S. spinal implant sales strengthened by new product introductions and robotics pull-through.

A look into three companies outside the U.S. in the $100 million to $300 million revenue bracket: LimaCorporate, Medartis and AK Medical.

Matt Woods, Founder of Ortho Consulting Group, touched on three key points as the European orthopedic market adapts in these unpredictable times: the cancellation of industry meetings due to COVID could slow the pace of innovation, EU Medical Device Regulation (MDR), and accelerating M&A activity.

Acumed and OsteoMed, both owned by Colson Medical, will gradually integrate over the coming year under the leadership of Acumed CEO Sharon Wolfington.